Avi Kapoor
CureVac NV
CVAC · NASDAQ
$4.66−$0.01 (−0.21%)TodayMarket closed ·
No price history for this range.
About CVAC
- Employees
- 904
- Headquarters
- Tuebingen, Baden-Wuerttemberg
- Listed
- Aug 14, 2020
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- curevac.com
CVAC key statistics
- Market cap
- 1.05B
- Price-earnings ratio
- 7.27
- Dividend yield
- —
- Average volume
- 1.52M
- Volume
- 1.15M
- Open price
- $4.57
- High today
- $4.67
- Low today
- $4.57
- 52 Week high
- $5.55
- 52 Week low
- $4.00
CureVac NV (CVAC) at a glance
CureVac NV (CVAC) last traded at $4.66, with a market cap of 1.05B and a price-to-earnings ratio of 7.27.
Today the stock has traded between $4.57 and $4.67. The current price is 2.0% above the day's low and 0.1% below its high.
Volume so far is 1.15M shares, below the average of 1.52M shares a day.
Over the past year CureVac NV has ranged from $4.00 to $5.55, and now sits 43% of the way up that range.
CureVac NV met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q3 FY25 it reported -$0.08 per share against an estimate of -$0.1148.
CVAC earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 3 of the last 8 quarters, by 75.7% on average.
- Q4 FY23: reported -$0.39 per share against an estimate of -$0.1887
- Q1 FY24: reported -$0.31 per share against an estimate of -$0.2326
- Q2 FY24: reported -$0.32 per share against an estimate of -$0.2703
- Q3 FY24: reported $1.50 per share against an estimate of $0.5738
- Q4 FY24: reported -$0.14 per share against an estimate of -$0.2168
- Q1 FY25: reported -$0.23 per share against an estimate of -$0.1938
- Q2 FY25: reported -$0.26 per share against an estimate of -$0.1862
- Q3 FY25: reported -$0.08 per share against an estimate of -$0.1148
CVAC news
- Vandana Singh
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
5 Stocks To Ride The German Market Rally
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, SOAR, MTWO on Behalf of Shareholders
- Avi Kapoor
Nasdaq Moves Higher; Oracle Shares Jump After Upbeat Q4 Results
- Vandana Singh
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
- Press releaseBusiness Wire
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
- Henry Khederian
CureVac (CVAC) Stock Rises After Q1 Update, Oncology Pipeline Gains Traction
Similar companies
Companies in the same industry as CureVac NV
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.